Please assess the completion status of the following clinical trial:

Trial Title: Imaging Apoptosis for Lymphoma Treatment Response

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria (Healthy Volunteers):~* Adult 18 years of age or older~* No known hematological disorders~* Considered healthy based on assessment by Principal Investigator (PI).~* Able to provide informed consent~* Able to comprehend and willing to follow instructions for study procedures as called for by the protocol.~* Capable of lying still and supine within the PET/CT scanner for up to 1 hour at a time.~Exclusion Criteria (Healthy Volunteers):~* No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents or illicit drugs) within the past year per self-reporting mechanisms.~* No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol specified imaging sessions.~* Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), non-lactating, OR of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 18 F-FAT) is negative~Inclusion Criteria (Participants with Diffuse Large B Cell Lymphoma):~* Men or women 18 years of age or older with a new diagnosis of lymphoma who will be treated with standard of care therapy for curative intent and at least one measurable (RECIST 1.1), FDG-avid lesion. OR recurrent DLBLC with at least one measurable (RECIST 1.1) FDA-avid lesion and a minimum of 12 months since last receiving treatment.~* If applicable at least one FDG avid lesion accessible for biopsy (ultrasound guided preferred)~* Able to provide informed consent~* Able to tolerate standard of care systemic therapy as recommended by referring physician(s).~Exclusion Criteria (Participants with Diffuse Large B Cell Lymphoma):~* Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), non-lactating, OR of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 18 F-FAT) is negative~* Not currently enrolled in another study using an investigational drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cohort 1 = Healthy Volunteers (Type: EXPERIMENTAL): * Healthy volunteers (N=6, three male, three female) will be recruited to undergo a single 18F-FAT PET/CT imaging session for radiation dosimetry estimates.~* 18F-FAT administration followed by body imaging at 3 time points~  * 0-60 min = multiple quick body scans~ * 120 min post injection = body scan~ * 240 min post injection = body scan
- Cohort 2a: Newly Diagnosed DLBCL patients being treated with R-CHOP (Type: EXPERIMENTAL): -N= 6 : 18F-FAT imaging session at baseline and Day 2-4 following Cycle 1 standard of care therapy.
- Cohort 2b: Newly Diagnosed DLBCL patients being treated with R-CHOP (Type: EXPERIMENTAL): -N=9: 18F-FAT imaging session at baseline and best time point determined from Cohort 2a (2 days post Cycle 1 standard of care therapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy